This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–e248.
SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, et al. Final report of a trial of intensive versus standard blood-pressure control. N. Engl J Med. 2021;384:1921–30.
American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022[J]. Diabetes Care. 2022;45:S144–74.
Kario K, Mogi M, Hoshide S. Latest hypertension research to inform clinical practice in Asia. Hypertens Res. 2022;45:555–72.
Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al. Trial of intensive blood-pressure control in older patients with hypertension. N. Engl J Med. 2021;385:1268–79.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–36.
Rakugi H. Step for breaking free from clinical inertia. Hypertens Res. 2022;45:5–7.
Zhang WL, Cai J. STEP to blood pressure management of elderly hypertension: evidence from Asia. Hypertens Res. 2022;45:576–82.
Ohkubo T. Utility of the “Strategy of Blood Pressure Intervention in Elderly Hypertensive Patients” for home blood pressure management in a real-world setting. Hypertens Res. 2022;45:8–10.
Kario K, Sakima A, Ohya Y. STEP to estimate cardiovascular events by home blood pressure in the era of digital hypertension. Hypertens Res. 2022;45:11–14.
Jiao Y, Sun Z, Xie Y, Zheng J, Li Z, Guo X, et al. Potential impacts of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline on Chinese adults and how to address them. BMC Cardiovasc Disord. 2020;20:237.
Yang C, Wang J, Gao B, Zhang Y, Wang F, Zhang L, et al. Prevalence and treatment of hypertension in China: impacts of 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline. Sci Bull. 2018;63:488–93.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Guo, RY., Guo, YF. The cutoff BP values for hypertension should not be lowered in China. Hypertens Res 45, 1526–1527 (2022). https://doi.org/10.1038/s41440-022-00969-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-022-00969-2